In addition, ROCK inhibitors or knocking down ROCK2 could attenuate the cognitive impairment and synaptic dysfunction induced by acrolein, suggesting that ROCK2 may be a potential target for the treatment of early AD. This evidence concerns the gene ROCK2 and Alzheimer disease.